These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Enzyme replacement therapy delays pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis. Whiting RE; Narfström K; Yao G; Pearce JW; Coates JR; Castaner LJ; Jensen CA; Dougherty BN; Vuillemenot BR; Kennedy D; O'Neill CA; Katz ML Exp Eye Res; 2014 Aug; 125():164-72. PubMed ID: 24954537 [TBL] [Abstract][Full Text] [Related]
24. Managing CLN2 disease: a treatable neurodegenerative condition among other treatable early childhood epilepsies. Mazurkiewicz-Bełdzińska M; Del Toro M; Haliloğlu G; Huidekoper HH; Kravljanac R; Mühlhausen C; Andersen BN; Prpić I; Striano P; Auvin S Expert Rev Neurother; 2021 Nov; 21(11):1275-1282. PubMed ID: 33538188 [TBL] [Abstract][Full Text] [Related]
25. Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration. Kim A; Grover A; Hammon K; de Hart G; Slasor P; Cherukuri A; Ajayi T; Jacoby D; Schulz A; Specchio N; de Los Reyes E; Gissen P; Henshaw JW Clin Transl Sci; 2021 Mar; 14(2):635-644. PubMed ID: 33202105 [TBL] [Abstract][Full Text] [Related]
26. Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 study. Cherukuri A; Cahan H; de Hart G; Van Tuyl A; Slasor P; Bray L; Henshaw J; Ajayi T; Jacoby D; O'Neill CA; Schweighardt B Clin Immunol; 2018 Dec; 197():68-76. PubMed ID: 30205177 [TBL] [Abstract][Full Text] [Related]
27. Development of the "Hamburg Best Practice Guidelines for ICV-Enzyme Replacement therapy (ERT) in CLN2 Disease" Based on 6 Years Treatment Experience in 48 Patients. Schwering C; Kammler G; Wibbeler E; Christner M; Knobloch JK; Nickel M; Denecke J; Baehr M; Schulz A J Child Neurol; 2021 Jul; 36(8):635-641. PubMed ID: 33543660 [TBL] [Abstract][Full Text] [Related]
28. Management Strategies for CLN2 Disease. Williams RE; Adams HR; Blohm M; Cohen-Pfeffer JL; de Los Reyes E; Denecke J; Drago K; Fairhurst C; Frazier M; Guelbert N; Kiss S; Kofler A; Lawson JA; Lehwald L; Leung MA; Mikhaylova S; Mink JW; Nickel M; Shediac R; Sims K; Specchio N; Topcu M; von Löbbecke I; West A; Zernikow B; Schulz A Pediatr Neurol; 2017 Apr; 69():102-112. PubMed ID: 28335910 [TBL] [Abstract][Full Text] [Related]
29. Cerebrospinal fluid neurofilament light chain levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment. Iwan K; Patel N; Heslegrave A; Borisova M; Lee L; Bower R; Mole SE; Mills PB; Zetterberg H; Mills K; Gissen P; Heywood WE F1000Res; 2021; 10():614. PubMed ID: 35106137 [TBL] [Abstract][Full Text] [Related]
33. Natural History Studies in NCL and Their Expanding Role in Drug Development: Experiences From CLN2 Disease and Relevance for Clinical Trials. Nickel M; Schulz A Front Neurol; 2022; 13():785841. PubMed ID: 35211079 [TBL] [Abstract][Full Text] [Related]